Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.

about

T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.

P2860

Q55009872-55998372-584C-48CC-97AB-B9D972032D12

P2860

Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q45072628

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@en

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@nl

type

Item

label

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@en

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@nl

prefLabel

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@en

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@nl

P1476

Topotecan combined with Ifosfa ...... in aggressive T-cell lymphoma.

@en

P2093

Mei Guan

http://www.w3.org/2001/XMLSchema#string

Ning Jia

http://www.w3.org/2001/XMLSchema#string

ShuChang Chen

http://www.w3.org/2001/XMLSchema#string

YaJuan Shao

http://www.w3.org/2001/XMLSchema#string

YuZhou Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.

Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates

L-asparaginase: a promising chemotherapeutic agent.

L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

P2888

s12032-014-0402-0

P304

402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-014-0402-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018804092

http://www.w3.org/2001/XMLSchema#string

P698

25428395

http://www.w3.org/2001/XMLSchema#string

Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.

about

P2860

P2860

Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698